Royalchem At CPHI Japan 2026 — Visit Us At Booth 3A-29, Tokyo Big Sight

Author: Site Editor  |  Publish Time: 2026-04-20  |  Origin: Site

Anhui Royal Chemical Co., Ltd. (Royalchem) is exhibiting at CPHI Japan 2026, April 21–23 at Tokyo Big Sight. Find our team at Booth 3A-29, East Hall 3, alongside close to 800 exhibitors from more than 70 countries across the co-located CPHI, ICSE, P-MEC, BioPh and InnoPack Japan shows.

Featured Products at Booth 3A-29

A focused selection across five product families that map to Japan's pharma, biotech and functional-food priorities:

• Pharmaceutical Intermediates — Pivaloyl Chloride (CAS 3282-30-2), 2,6-Difluoroaniline (CAS 5509-65-9), 5-Fluorouracil (CAS 51-21-8) — for API synthesis in oncology, antiviral and CNS programs.

• Specialty Reagents — Trifluoroacetic Acid / TFA (CAS 76-05-1) for solid-phase peptide synthesis, Triphenylphosphine (CAS 603-35-0), and Sodium / Lithium Borohydride (CAS 16940-66-2 / 16949-15-8).

• Solvents & Carbonates — Acetonitrile (CAS 75-05-8), DMSO (CAS 67-68-5), THF (CAS 109-99-9), and the DMC / DEC / EMC carbonate family (CAS 616-38-6 / 105-58-8 / 623-53-0) for pharma and electronic-grade applications.

• Silane Coupling Agents — TBDMSCl (CAS 18162-48-6) and TBDPSCl (CAS 58479-61-1) for selective hydroxyl protection in complex API synthesis, plus the 3-Mercaptopropyl-trimethoxy- / triethoxy-silane family (CAS 4420-74-0 / 14814-09-6) for adhesives and composites.

• Bioactive & Nutraceutical Ingredients — γ-Aminobutyric Acid / GABA (CAS 56-12-2), α-Lipoic Acid (CAS 1077-28-7), L-Alanine (CAS 56-41-7), Cysteamine Hydrochloride (CAS 156-57-0).

Download the Bilingual (EN / JP) Product Catalog

Why Japan Now

• A structural-growth intermediates market. The global pharmaceutical intermediates market is sized at roughly USD 38 billion in 2025, with mid-single-digit annual growth expected through 2035 as outsourcing to specialized CDMOs deepens. Japan's high generic penetration and strict quality culture create steady demand for documented, compliant supply.

• Peptide therapeutics keep lifting high-purity TFA. Multiple market trackers project double-digit annual growth in pharma-grade TFA through the late 2020s, driven by solid-phase peptide synthesis. Batch consistency and ultra-low metals are the conversation we want to have at the booth.

• A Japanese functional-food opportunity. GABA has ranked among the most-used ingredients under Japan's Food with Function Claims (FFC) framework for several consecutive reporting years, anchoring stress, sleep and blood-pressure claims.

Sustainability — EcoVadis Silver + 100% Renewable Electricity

Royalchem holds an EcoVadis Silver Rating (Top 15%, September 2025), and in March 2026 reached 100% renewable office electricity via 18 MWh of Green Electricity Certificates. TfS / PSCI documentation is available on request.

Plan Your Visit

Booth: 3A-29, East Hall 3
Dates: April 21 – 23, 2026 · 10:00 – 17:00 daily
Venue: Tokyo Big Sight — 3-11-1 Ariake, Koto City, Tokyo
Nearest stations: Kokusai-Tenjijo (Rinkai Line) · Tokyo Big Sight (Yurikamome Line)

To pre-book a meeting, email marketing@royal-chem.com with your area of interest (intermediates, solvents, silanes, or bioactives). Walk-ins welcome on all three days.

Tags: CPHI Japan 2026 · Pharmaceutical Intermediates · Tokyo Big Sight · API Synthesis · Peptide Synthesis · Trifluoroacetic Acid · GABA · Silane Coupling Agents · Royal Chemical · Japan Pharma Exhibition